AlphaYou
Overview
Smart money at a glance
Filings to Sep 30, 2026Net selling: insiders sold $12.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$12.5M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 2 cutEven
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 29- Open
- $58.19
- 52-wk high
- $64.38
- High
- $58.48
- 52-wk low
- $34.56
- Low
- $57.51
- Prev close
- $58.37
- Mkt cap
- $33.73B
- P/E
- 31.2x
- Volume
- 2.84M
- Fwd P/E
- 29.4x
- Beta
- 0.43
- Div yield
- 1.56%
- P/S
- 13.3x
- P/B
- 3.8x
- Profit margin
- +32.0%
- Op margin
- +19.8%
- ROE
- +14.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about RPRX filings
Are insiders buying or selling Royalty Pharma Plc (RPRX) stock?
Net selling: insiders sold $12.5M and bought $0 of RPRX stock on the open market in the 90 days to Sep 30, 2026, according to SEC Form 4 filings. $12.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Hite, Christopher (EVP & Chairman, Partnering), who sold $11.9M. The latest filing was on Sep 24, 2026.
Which members of Congress have traded RPRX recently?
None. No member of Congress disclosed a RPRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this RPRX smart-money data?
This summary uses filings available on Sep 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- BR
Bridgewater
$12.3M
bought
Sells/Trims (2)
- SQ
Squarepoint
$46.4M
trimmed
- DS
D.E. Shaw
$24.4M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in RPRX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 3.9% above what analysts expected.
Earnings per share
$1.27 expected
Revenue
$758.9M expected
The release did not provide a source-backed EPS figure.
FY2026 guidance
$3.40B to $3.50B
No comparable estimate
Reports Nov 4, 2026, in 35 days
Estimates as of Sep 30, 2026
EPS expected
$1.14 to $1.22
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $609.3M | $622.0M | $630.6M | $674.1M |
| Cost of what it sold | $1.3M | $1.2M | $1.2M | $268.2M |
| Gross profit | $609.3M | $622.0M | $629.4M | $405.9M |
| What it spent | ||||
| Research and development | $50.5M | $51.0M | $40.0M | $97.9M |
| Sales and admin | $118.7M | $164.3M | $159.0M | $161.9M |
| Other operating costs | $12.9M | $18.3M | -$202.1M | $13.1M |
| Total operating expenses | $182.1M | $233.6M | -$3.1M | $272.8M |
| What was left | ||||
| Operating profit | $427.2M | $388.4M | $632.5M | $133.0M |
| Interest on debt | $79.6M | $94.2M | $93.7M | $93.6M |
| Profit before tax | $444.2M | $355.9M | $468.3M | $81.5M |
| Tax | $156.0M | $142.0M | $173.0M | — |
| Net profit | $288.2M | $214.2M | $295.0M | $17.9M |
| EBITDA | $525.1M | $451.3M | $563.1M | $176.4M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bearish
Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD
NeutralSep 29Royalty Pharma officer proposes $239K share sale | RPRX SEC Filing - Form 144
NeutralSep 28Form 4 Royalty Pharma Plc For: 25 September By Investing.com
NeutralSep 25Royalty Pharma EVP Christopher Hite sells $5.85m in shares
NeutralSep 25A prearranged plan governed SCH Investment Partners’ sale of 100,000 Royalty Pharma (RPRX) shares.
Leans bearishSep 24Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares
NeutralSep 23Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price, Quote, News & History
NeutralSep 19
Macro
10 macro signals shaping RPRX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results